Direct-acting agents (DAAs) have demonstrated “astounding” success rates in the treatment of hepatitis C (HCV), making treatment failures rare. Indeed, failures may catch practitioners by surprise since cure rates range from about 95% to 100%. But non-response does happen, and key causes include virus genotype, the presence of liver cirrhosis, viral treatment resistance, and genetic heritage.
